{"success":true,"data":{"pressRelease":{"id":"117601","rtpr_id":"nWkr5ddhBb","ticker":"CLSRB","exchange":"Nasdaq Stockholm","all_tickers":["CLSRB"],"title":"Last Day of Subscription in Clinical Laserthermia Systems AB' Rights Issue of Units is 18 August 2026","author":"Cision","published_at":"2026-08-13T06:30:03.703Z","article_body":"CLS\nNOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY,\nIN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW\nZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, RUSSIA, BELARUS, OR ANY OTHER\nJURISDICTION WHERE THE RELEASE, DISTRIBUTION, OR PUBLICATION OF THIS PRESS\nRELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER\nMEASURES. SEE THE SECTION \"LEGAL RIGHTS AND IMPORTANT INFORMATION\" IN THE\nPRESS RELEASE PUBLISHED 23 JULY 2026.\n\n\nTuesday, 18 August 2026, is the last day for subscription in Clinical\nLaserthermia Systems AB’ (publ) (“CLS” or the “Company”) rights\nissue of units, consisting of shares and warrants, with preferential rights\nfor the Company's existing shareholders (the \"Rights Issue\"), which was\nresolved by the Board of Directors on 22 July 2026. The subscription period\nruns from 4 August 2026 until 18 August 2026. The initial issue volume amounts\nto approximately SEK 39.5 million and is covered by pre-subscription and\nguarantee undertakings totalling approximately SEK 29 million, corresponding\nto approximately 73.4 percent of the Rights Issue. Please note that each bank\nmay have different deadlines. This announcement is for informational purposes\nonly and does not constitute an offer to subscribe for or purchase securities.\nFor full terms and conditions of the Issue, reference is made to the company\nannouncement published on 23 July 2026.\n\n\n\nSummary of the Rights Issue:\n* Shareholders who were registered in the share register maintained by\nEuroclear Sweden AB as of the record date, 31 July 2026, have received one (1)\nunit right for each share held on the record date. Six (6) unit rights entitle\nthe holder to subscribe for one (1) unit. One (1) unit consists of four (4)\nnew B-shares and three (3) warrants of series TO 9 B (\"Unit\").\n* The Rights Issue comprises a maximum of 5,194,432 units, corresponding to a\nmaximum of 20,777,728 new B-shares and a maximum of 15,583,296 warrants of\nseries TO 9 B.\n* The subscription price amounts to SEK 7.60 per unit, corresponding to SEK\n1.90 per new B-share. Warrants of series TO 9 B are issued free of charge.\n* Upon full subscription of the Rights Issue, the Company will initially be\nprovided with approximately SEK 39.5 million before deduction of\ntransaction-related costs.\n* The net proceeds from the Rights Issue will be used primarily for\nacceleration of the commercialization and market penetration of PRISM Neuro\nLaser Therapy System, core operations and working capital as well as expansion\nof the Company's partnership model.\n* Under the assumption of full subscription of the initial Rights Issue and\nfull exercise of all warrants of series TO 9 B, the Company may receive\nadditional proceeds of approximately SEK 29.6 million before deduction of\ntransaction-related costs.\n* The subscription period for the Rights Issue commenced 4 August 2026 and\nends on 18 August 2026.\n* The Rights Issue is covered by subscription and guarantee undertakings\namounting to approximately SEK 29 million, corresponding to approximately 73.4\npercent of the Rights Issue.\n \n\nAdvisors\n\nGemstone Capital ApS is acting as financial advisor and Foyen Advokatfirma is\nacting as legal advisor to CLS in connection with the Rights Issue. Vator\nSecurities AB is acting as issuing agent.\n\n \n\n \n\nFor more information, please contact:\n\nDan J. Mogren, CEO Clinical Laserthermia Systems AB (publ)\n\nPhone: +46 (0)705 90 11 40\n\nE-mail: dan.mogren@clinicallaser.com\n\n \n\n \n\nAbout CLS\n\nClinical Laserthermia Systems AB (publ), develops and sells TRANBERG® Thermal\nTherapy System and ClearPoint Prism® Neuro Laser Therapy System with sterile\ndisposables, for minimally invasive treatment of cancer tumors and\ndrug-resistant epilepsy. The products are marketed and sold through partners\nfor image-guided laser ablation. CLS is headquartered in Lund, Sweden, with\nsubsidiaries in Germany, the United States and a marketing company in\nSingapore. CLS is listed on Nasdaq First North Growth Market under the symbol\nCLS B. Certified adviser (CA) is FNCA Sweden AB.\n\n \n\nFor more information about CLS, please visit the Company's website:\nwww.clinicallaser.se\n\n \n\n \n\nInformation to distributors\n\nIn order to comply with the product governance requirements contained in: (a)\nDirective 2014/65/EU of the European Parliament and of the Council on markets\nin financial instruments, as amended (\"MiFID II\"); (b) Articles 9 and 10 of\nCommission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c)\nnational implementing measures (together, the \"MiFID II Product Governance\nRequirements\"), and disclaiming all and any liability, whether arising in\ntort, contract or otherwise, which any \"manufacturer\" (for the purposes of the\nMiFID II Product Governance Requirements) may otherwise have with respect\nthereto, the securities offered have been subject to a product approval\nprocess, which has determined that such securities are: (i) compatible with an\nend target market of retail investors and investors who meet the criteria of\nprofessional clients and eligible counterparties, each as defined in MiFID II;\nand (ii) eligible for distribution through all distribution channels as are\npermitted by MiFID II (the \"Target Market Assessment\"). Notwithstanding the\nTarget Market Assessment, distributors should note that: the price of the\nCompany's shares or warrants may decline and investors could lose all or part\nof their investment; the Company's shares and warrants offer no guaranteed\nincome and no capital protection; and an investment in the Company's shares or\nwarrants is compatible only with investors who do not need a guaranteed income\nor capital protection and who (either alone or in conjunction with an\nappropriate financial or other adviser) are capable of evaluating the merits\nand risks of such an investment and who have sufficient resources to be able\nto bear any losses that may result therefrom. The Target Market Assessment is\nwithout prejudice to the requirements of any contractual, legal or regulatory\nselling restrictions in relation to the Rights Issue. For the avoidance of\ndoubt, the Target Market Assessment does not constitute: (a) an assessment of\nsuitability or appropriateness for the purposes of MiFID II; or (b) a\nrecommendation to any investor or group of investors to invest in, or\npurchase, or take any other action whatsoever with respect to the Company's\nshares or warrants. Each distributor is responsible for undertaking its own\nTarget Market Assessment in respect of the Company's shares and warrants and\ndetermining appropriate distribution channels.\n\n \n\nhttps://news.cision.com/cls/r/last-day-of-subscription-in-clinical-laserthermia-systems-ab--rights-issue-of-units-is-18-august-202%2Cc4382764\n\nPR - CLS Last day of subscription 18 Aug_EN\n(https://mb.cision.com/Main/11591/4382764/4217140.pdf)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr5ddhBb","title":"Last Day of Subscription in Clinical Laserthermia Systems AB' Rights Issue of Units is 18 August 2026","author":"Cision","ticker":"CLSRB","created":"2026-08-13T06:30:03.703Z","tickers":["CLSRB"],"exchange":"Nasdaq Stockholm","article_body":"CLS\nNOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY,\nIN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW\nZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, RUSSIA, BELARUS, OR ANY OTHER\nJURISDICTION WHERE THE RELEASE, DISTRIBUTION, OR PUBLICATION OF THIS PRESS\nRELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER\nMEASURES. SEE THE SECTION \"LEGAL RIGHTS AND IMPORTANT INFORMATION\" IN THE\nPRESS RELEASE PUBLISHED 23 JULY 2026.\n\n\nTuesday, 18 August 2026, is the last day for subscription in Clinical\nLaserthermia Systems AB’ (publ) (“CLS” or the “Company”) rights\nissue of units, consisting of shares and warrants, with preferential rights\nfor the Company's existing shareholders (the \"Rights Issue\"), which was\nresolved by the Board of Directors on 22 July 2026. The subscription period\nruns from 4 August 2026 until 18 August 2026. The initial issue volume amounts\nto approximately SEK 39.5 million and is covered by pre-subscription and\nguarantee undertakings totalling approximately SEK 29 million, corresponding\nto approximately 73.4 percent of the Rights Issue. Please note that each bank\nmay have different deadlines. This announcement is for informational purposes\nonly and does not constitute an offer to subscribe for or purchase securities.\nFor full terms and conditions of the Issue, reference is made to the company\nannouncement published on 23 July 2026.\n\n\n\nSummary of the Rights Issue:\n* Shareholders who were registered in the share register maintained by\nEuroclear Sweden AB as of the record date, 31 July 2026, have received one (1)\nunit right for each share held on the record date. Six (6) unit rights entitle\nthe holder to subscribe for one (1) unit. One (1) unit consists of four (4)\nnew B-shares and three (3) warrants of series TO 9 B (\"Unit\").\n* The Rights Issue comprises a maximum of 5,194,432 units, corresponding to a\nmaximum of 20,777,728 new B-shares and a maximum of 15,583,296 warrants of\nseries TO 9 B.\n* The subscription price amounts to SEK 7.60 per unit, corresponding to SEK\n1.90 per new B-share. Warrants of series TO 9 B are issued free of charge.\n* Upon full subscription of the Rights Issue, the Company will initially be\nprovided with approximately SEK 39.5 million before deduction of\ntransaction-related costs.\n* The net proceeds from the Rights Issue will be used primarily for\nacceleration of the commercialization and market penetration of PRISM Neuro\nLaser Therapy System, core operations and working capital as well as expansion\nof the Company's partnership model.\n* Under the assumption of full subscription of the initial Rights Issue and\nfull exercise of all warrants of series TO 9 B, the Company may receive\nadditional proceeds of approximately SEK 29.6 million before deduction of\ntransaction-related costs.\n* The subscription period for the Rights Issue commenced 4 August 2026 and\nends on 18 August 2026.\n* The Rights Issue is covered by subscription and guarantee undertakings\namounting to approximately SEK 29 million, corresponding to approximately 73.4\npercent of the Rights Issue.\n \n\nAdvisors\n\nGemstone Capital ApS is acting as financial advisor and Foyen Advokatfirma is\nacting as legal advisor to CLS in connection with the Rights Issue. Vator\nSecurities AB is acting as issuing agent.\n\n \n\n \n\nFor more information, please contact:\n\nDan J. Mogren, CEO Clinical Laserthermia Systems AB (publ)\n\nPhone: +46 (0)705 90 11 40\n\nE-mail: dan.mogren@clinicallaser.com\n\n \n\n \n\nAbout CLS\n\nClinical Laserthermia Systems AB (publ), develops and sells TRANBERG® Thermal\nTherapy System and ClearPoint Prism® Neuro Laser Therapy System with sterile\ndisposables, for minimally invasive treatment of cancer tumors and\ndrug-resistant epilepsy. The products are marketed and sold through partners\nfor image-guided laser ablation. CLS is headquartered in Lund, Sweden, with\nsubsidiaries in Germany, the United States and a marketing company in\nSingapore. CLS is listed on Nasdaq First North Growth Market under the symbol\nCLS B. Certified adviser (CA) is FNCA Sweden AB.\n\n \n\nFor more information about CLS, please visit the Company's website:\nwww.clinicallaser.se\n\n \n\n \n\nInformation to distributors\n\nIn order to comply with the product governance requirements contained in: (a)\nDirective 2014/65/EU of the European Parliament and of the Council on markets\nin financial instruments, as amended (\"MiFID II\"); (b) Articles 9 and 10 of\nCommission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c)\nnational implementing measures (together, the \"MiFID II Product Governance\nRequirements\"), and disclaiming all and any liability, whether arising in\ntort, contract or otherwise, which any \"manufacturer\" (for the purposes of the\nMiFID II Product Governance Requirements) may otherwise have with respect\nthereto, the securities offered have been subject to a product approval\nprocess, which has determined that such securities are: (i) compatible with an\nend target market of retail investors and investors who meet the criteria of\nprofessional clients and eligible counterparties, each as defined in MiFID II;\nand (ii) eligible for distribution through all distribution channels as are\npermitted by MiFID II (the \"Target Market Assessment\"). Notwithstanding the\nTarget Market Assessment, distributors should note that: the price of the\nCompany's shares or warrants may decline and investors could lose all or part\nof their investment; the Company's shares and warrants offer no guaranteed\nincome and no capital protection; and an investment in the Company's shares or\nwarrants is compatible only with investors who do not need a guaranteed income\nor capital protection and who (either alone or in conjunction with an\nappropriate financial or other adviser) are capable of evaluating the merits\nand risks of such an investment and who have sufficient resources to be able\nto bear any losses that may result therefrom. The Target Market Assessment is\nwithout prejudice to the requirements of any contractual, legal or regulatory\nselling restrictions in relation to the Rights Issue. For the avoidance of\ndoubt, the Target Market Assessment does not constitute: (a) an assessment of\nsuitability or appropriateness for the purposes of MiFID II; or (b) a\nrecommendation to any investor or group of investors to invest in, or\npurchase, or take any other action whatsoever with respect to the Company's\nshares or warrants. Each distributor is responsible for undertaking its own\nTarget Market Assessment in respect of the Company's shares and warrants and\ndetermining appropriate distribution channels.\n\n \n\nhttps://news.cision.com/cls/r/last-day-of-subscription-in-clinical-laserthermia-systems-ab--rights-issue-of-units-is-18-august-202%2Cc4382764\n\nPR - CLS Last day of subscription 18 Aug_EN\n(https://mb.cision.com/Main/11591/4382764/4217140.pdf)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-08-13T06:30:03.804095711Z","server_sent_at_ms":1786602603804},"received_at":"2026-08-13T06:30:03.853Z","source_url":"https://news.cision.com/cls/r/last-day-of-subscription-in-clinical-laserthermia-systems-ab--rights-issue-of-units-is-18-august-202%2Cc4382764"},"analysis":null,"durationMs":null,"modelName":null}}